![Steven N. Gordon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Steven N. Gordon
Directeur Administratif chez Kadmon Corp. LLC
Postes actifs de Steven N. Gordon
Sociétés | Poste | Début | Fin |
---|---|---|---|
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Directeur Administratif | - | - |
Compliance Officer | - | - | |
Conseiller Juridique Général | - | - | |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | Directeur des opérations | - | - |
Conseiller Juridique Général | - | - |
Historique de carrière de Steven N. Gordon
Anciens postes connus de Steven N. Gordon
Sociétés | Poste | Début | Fin |
---|---|---|---|
KADMON HOLDINGS, INC. | Directeur Administratif | 01/01/2009 | 30/08/2019 |
Compliance Officer | 01/01/2009 | 30/08/2019 | |
Fondateur | 01/01/2009 | 30/08/2019 | |
Conseiller Juridique Général | 01/01/2009 | 30/08/2019 | |
Secrétaire Général | 01/01/2009 | 30/08/2019 |
Formation de Steven N. Gordon
Bar-Ilan University | Undergraduate Degree |
Touro College Jacob D. Fuchsberg Law Center | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Israël | 2 |
Opérationnelle
General Counsel | 3 |
Chief Administrative Officer | 2 |
Compliance Officer | 2 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Health Technology |
Kadmon Holdings, Inc.
![]() Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | Health Technology |
- Bourse
- Insiders
- Steven N. Gordon
- Expérience